Patent · US Active

Method of treating Tourette'S disorder with GABA-aminotransferase inactivators

US9254274B2 · kind B2 · utility

0Cited by

1References

37Claims

0Family size

Assignees

Catalyst Pharmaceuticals, Inc. · US
NEW YORK UNIVERSITY · US
The Feinstein Institutes for Medical Research · US

Inventors

Steven Miller · Brisbane, AU
Jonathan D. Brodie · Cos Cob, US
Stephen L. Dewey · Manorville, US

Key dates

Filing date	Jul 25, 2014
Grant date	Feb 9, 2016
Priority date	—
Expiry date	Aug 4, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.